A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors

Disease Area: Solid Tumors
Investigator: Dennis Slamon
Institution: University of California, Los Angeles
CIRM Grant: DR3-07067 (Closed)
Award Value: $5,683,693
Trial Sponsor: University Health Network, Toronto
Trial Stage: Phase 1
Trial Status: Recruiting
Targeted Enrollment: 48
ClinicalTrials.gov ID: NCT01954316

Details:
Solid tumors are the most prevalent form of cancer, and are a major cause of death worldwide. A team at UCLA is testing a drug for the treatment of cancer that works by blocking PLK4, a protein that is important in regulating cell growth, division and death. This protein is important for the survival of the cancer stem cell as well as the rest of the cells in a tumor. It is hypothesized that blocking this protein from working in the tumor may stop or even shrink tumor growth.

Design:
Dose escalation and expansion.

Goal:
Determination of maximum tolerated dose and recommended Phase 2 dose. Safety, PK. Efficacy in solid cancers.

Updates:
Ongoing.

Contact Trial Sponsor